 SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 PRNewswire -- IDEAYA Biosciences, Inc. NASDAQ: IDYA, a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 12 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma MUM ClinicalTrials.gov Identifier: NCT03947385. 